Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01372345 | Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Fasting Conditions | PHASE1 | COMPLETED | 43 | — | — | Feb 1, 2005 | Mar 1, 2005 | Jun 13, 2011 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Ciprofloxacin | EXPERIMENTAL | Ciprofloxacin Extended Release Tablets of Dr. Reddy's Laboratories Limited |
| CIPRO®XR | ACTIVE_COMPARATOR | CIPRO® XR (Bayer Health Care, Bayer Pharmaceuticals Corporation) Tablets |
| Name | Type | Description |
|---|---|---|
| CIPRO®XR | DRUG | Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited |
Inclusion Criteria: 1. Non-institutionalized subjects consisting of members of, the coInmunity at large. 2. All subjects selected for this study will be non-smokers between 18 and 45 years of age (inclusive). Female subjects must be unable to become pregnant (postmenopausal for at least 1 year, or ...